USPTO serial 79280613
RYVU
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 2, 2021
- Examiner
- BERNS, LEE ANNE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with RYVU?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,046*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Claudia W. Stangle
Claudia W. Stangle Leydig, Voit & Mayer, Ltd.180 N. Stetson AveTwo Prudential PlazaChicago, IL 60601Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations being additives for use in the manufacture of pharmaceuticals; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical products for biotechnological purposes, namely, chemicals for use in biotechnological research and product development; chemicals for use in the agrochemical industry | ACTIVE | — |
| 005 | Chemico-pharmaceutical preparations, namely, chemical preparations for pharmaceutical purposes, namely, for the treatment of cancer and for use in immunology and oncology; chemical preparations for pharmaceutical purposes for the treatment of cancer and for use in immunology and oncology; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of cancer; biotechnological preparations for medical use in the nature of biological preparations for the treatment of cancer and for use immunology and oncology; medicines for human purposes, namely, medicines for the treatment of cancer and for use in immunology and oncology; adjuvants for medical purposes; biological tissue cultures for medical purposes; biological preparations being biological tissue cultures for veterinary purposes; biological preparations for medical purposes, namely, for treatment of cancer and for use in immunology and oncology; drug delivery agents consisting of compounds that facilitate the delivery of pharmaceutical preparations; medical preparations, namely, for treatment of cancer and for use in oncology; diagnostic preparations and materials being diagnostic preparations for medical purposes; chemical preparations for medical purposes namely, for treatment of cancer and for use in immunology and oncology; immunomodulators being a type of pharmaceutical preparation for the treatment of cancer; immunostimulants; immunoassay reagents for medical use; chemotherapeutics; chemical reagents for medical or veterinary purposes; biological preparations for the treatment of cancer; mixed biological preparations for medical purposes, namely, for the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations and substances, namely, for treatment of cancer and for use in immunology and oncology; anti-cancer preparations | ACTIVE | — |
| 009 | Downloadable computer software for use with medical diagnosis, research, and treatment, namely, for analyzing medical data and diagnosing medical conditions, for evaluation of suggested medical treatment, analyzing and evaluating medical data for mitigation or prevention of disease, for processing data related to clinical trials, and for use with the development, production, and research of pharmaceuticals, namely, data processing, data analysis and data evaluation, processing and analyzing data related to clinical trials, evaluating and analyzing pharmaceutical ingredients and facilitating formulation and administration of pharmaceuticals | ACTIVE | — |
| 042 | Research and development services in the field of immunology; chemistry services, namely, research in the field of immunology and oncology; chemical laboratories; chemistry consultation; testing of chemicals; chemical analysis; scientific research relating to chemistry; chemical research laboratory services; research and development services in the field of chemistry; provision of scientific information relating to the chemical industry; preparation of reports relating to chemical research; research and development in the pharmaceutical and biotechnology fields; laboratory research services relating to pharmaceuticals; information technology consultancy services for the pharmaceutical and healthcare industries; scientific research; computer aided scientific research services; biochemical research and analysis; genetic research; clinical research in the field of immunology and oncology; biological research; biological analysis; scientific research relating to biology; custom development of biological samples for research purposes; medical research; research to develop new products; research in the field of gene therapy; research and development in the field of diagnostic preparations; information on the subject of scientific research in the field of biochemistry and biotechnology; consultancy relating to pharmaceutical research; scientific research for medical purposes in the area of cancerous diseases; pharmaceutical products development; pharmaceutical product evaluation; testing of pharmaceuticals; conducting clinical trials for others for pharmaceutical products; research on the subject of pharmaceuticals; scientific laboratory services; scientific research services relating to the isolation and cultivation of human tissues and cells; computer aided scientific testing in the field of immunology and oncology; scientific and technological design, namely, design in the fields of biochemistry and biotechnology, namely, custom design of pharmaceuticals, chemicals, biological preparations, scientific software, pharmaceutical software, medical software, medical instruments and devices; software design and development; design and development of medical technology, namely, technology research in the field of medical instruments and devices; design and development of software for database management; pharmaceutical research and development; providing scientific information about the results of clinical trials for pharmaceutical products; technological research, namely, research in the field of pharmaceuticals; engineering services relating to computers, namely, computer-aided engineering services for the biotechnology industry; computer systems analysis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Ryvu Therapeutics SA
- Other trademarks owned by Ryvu Therapeutics SA
- Other trademarks owned by Ryvu Therapeutics SA
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named RYVU
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 2, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 20, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 2, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 2, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 2, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 2, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 15, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 15, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 25, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 11, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 11, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 11, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 11, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 11, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 21, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 20, 2020 | ALIE | ASSIGNED TO LIE | — |
| Oct 20, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 20, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 20, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 8, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 8, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 8, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 6, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 6, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 6, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 6, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 6, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 24, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 8, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 8, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 20, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 19, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 17, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 13, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 13, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 12, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |